Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inclacumab for reducing 90-day VOC readmission in sickle cell disease
2020-005287-60Phase 3Completed
- Sponsor
- Global Blood Therapeutics, Inc.
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in sickle cell disease (SCD) comparing Inclacumab with Placebo (2 arms). Primary endpoint: Proportion of participants with at least 1 recurrent vaso-occlusive crisis requiring healthcare-facility admission within 90 days. Started Jun 2021; status: completed.
02
Drugs
inclacumab
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2020-005287-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005287-60.